PMID: 2504876Sep 1, 1989Paper

The specificity of rejection and the absence of susceptibility of pancreatic islet beta cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat

The Journal of Experimental Medicine
R SuttonP J Morris

Abstract

The specificity of rejection of isolated pancreatic islets was examined in the rat using a quantitative model in which syngeneic (DA) or a mixture of syngeneic and allogeneic (DA and LEW or PVG) islets were implanted beneath the capsule of the kidney of nondiabetic normal rats (DA). 3 wk after transplantation total insulin extraction assays of the kidney with its islet implant together with immunohistological examination of the site of transplantation for evidence of syngeneic or allogeneic tissue demonstrated the total destruction of allogeneic islets without any evidence of damage to syngeneic islets either distant or in immediate proximity to allogeneic islets. Pancreatic islets, and especially beta cells, appear to be particularly vulnerable to the effector arm of both autoimmune and alloimmune responses, a vulnerability that has been attributed to the cytotoxic effects of lymphokines, notably IL-1, released in both autoimmune and alloimmune responses. The experiments reported here demonstrate not only the exquisite specificity of the allograft reaction but are not compatible with a hypothesis that B cells within an intact islet are nonspecifically susceptible to destruction by lymphokines.

References

Mar 1, 1976·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·K FederlinK Helmke
Nov 1, 1976·Transplantation·D R Finch, P J Morris
Jul 1, 1987·Diabetes/metabolism Reviews·J NerupJ Mølvig
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A S Rosenberg, A Singer
Jan 1, 1985·Annual Review of Immunology·S K DurumJ J Oppenheim
Dec 1, 1986·Transplantation·R SuttonP J Morris
Oct 1, 1986·Transplantation·M GotohA P Monaco
Jun 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·S Koide, R M Steinman
Jan 1, 1986·Annual Review of Immunology·D W Mason, P J Morris
Jun 1, 1974·The Journal of Surgical Research·M M ZieglerC F Barker
Dec 15, 1967·Science·B Mintz, W K Silvers
Mar 1, 1980·Transplantation·J R NashP R Bell
Feb 1, 1984·The Journal of Surgical Research·J R Nash, P R Bell
Jun 1, 1984·Transplantation·R W SchwizerR Evans
Mar 18, 1983·Science·C E MorrowF H Bach
Aug 1, 1983·Transplantation·H Reece-SmithP J Morris
Jan 1, 1980·Diabetes·P J MorrisP R Millard

❮ Previous
Next ❯

Citations

Mar 1, 1991·Diabetes/metabolism Reviews·C BoitardJ F Bach
Sep 1, 1996·Diabetologia·T Mandrup-Poulsen
Sep 1, 1994·Diabetologia·C BoitardJ F Bach
Nov 21, 2009·Cell Death and Differentiation·H E ThomasT W H Kay
Jan 1, 1990·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·C Boitard
Jul 16, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Govindarajan ThangaveluColin C Anderson
Apr 15, 1997·Transplantation·K R AhmedK K Gaal
Mar 21, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jeffrey L Platt
Jan 1, 1990·Current Eye Research·C Boitard
Jul 9, 1999·Diabetes/metabolism Research and Reviews·D W Gray
Jan 19, 2002·Annals of the New York Academy of Sciences·R G Gill
Aug 27, 1998·Biochemical Pharmacology·A Rabinovitch, W L Suarez-Pinzon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.